Collegium Pharmaceutical, Inc. (COLL) Financial Ratios
13 years of historical data (2013–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↓
4.53
↓-35% vs avg
5yr avg: 6.93
30Y Low4.8·High9.7
P/FCF
↓
3.61
↓-40% vs avg
5yr avg: 5.99
30Y Low3.9·High32.3
P/B Ratio
↑
4.80
-6% vs avg
5yr avg: 5.11
30Y Low2.8·High7.9
ROE
↓
23.7%
↓+13% vs avg
5yr avg: 21.0%
30Y Low-290%·High37%
Debt/EBITDA
↓
2.28
↓-19% vs avg
5yr avg: 2.81
30Y Low0.1·High4.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
COLL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Collegium Pharmaceutical, Inc. trades at 21.1x earnings, 11% above its 5-year average of 19.0x, sitting at the 40th percentile of its historical range. This is roughly in line with the Healthcare sector median P/E of 22.1x. On a free-cash-flow basis, the stock trades at 3.6x P/FCF, 40% below the 5-year average of 6.0x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.2B | $1.8B | $1.2B | $1.3B | $785M | $767M | $704M | $688M | $566M | $559M | $378M |
| Enterprise Value | $1.9B | $2.5B | $1.9B | $1.7B | $1.3B | $839M | $797M | $540M | $431M | $441M | $229M |
| P/E Ratio → | 21.10 | 26.76 | 15.40 | 23.86 | — | 10.04 | 26.36 | — | — | — | — |
| P/S Ratio | 1.52 | 2.35 | 1.83 | 2.27 | 1.69 | 2.77 | 2.27 | 2.32 | 2.02 | 19.62 | 220.79 |
| P/B Ratio | 4.80 | 6.09 | 5.06 | 6.58 | 4.03 | 3.78 | 3.78 | 7.87 | 6.18 | 5.37 | 2.80 |
| P/FCF | 3.61 | 5.61 | 5.70 | 4.69 | 6.40 | 7.55 | — | 32.25 | 3.90 | — | — |
| P/OCF | 3.59 | 5.58 | 5.65 | 4.68 | 6.32 | 7.40 | 7.49 | 24.78 | 3.34 | — | — |
P/E links to full P/E history page with 30-year chart
COLL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Collegium Pharmaceutical, Inc.'s enterprise value stands at 4.5x EBITDA, 35% below its 5-year average of 6.9x. The Healthcare sector median is 14.1x, placing the stock at a 68% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.24 | 3.08 | 3.04 | 2.85 | 3.03 | 2.57 | 1.82 | 1.54 | 15.50 | 133.66 |
| EV / EBITDA | 4.53 | 6.12 | 5.74 | 5.44 | 7.66 | 9.70 | 6.76 | — | 4.77 | — | — |
| EV / EBIT | 10.01 | 14.45 | 11.28 | 10.82 | 38.42 | 47.57 | 14.11 | — | — | — | — |
| EV / FCF | — | 7.72 | 9.58 | 6.28 | 10.77 | 8.26 | — | 25.30 | 2.97 | — | — |
COLL Profitability
Margins and return-on-capital ratios measuring operating efficiency
Collegium Pharmaceutical, Inc. earns an operating margin of 24.0%. Operating margins have compressed from 29.5% to 24.0% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 23.7% indicates solid capital efficiency. ROIC of 14.0% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.3% | 59.3% | 59.8% | 57.5% | 45.2% | 54.4% | 58.0% | 34.7% | 40.9% | 90.9% | 87.6% |
| Operating Margin | 24.0% | 24.0% | 26.9% | 29.5% | 7.2% | 6.4% | 18.1% | -8.0% | -7.4% | -264.9% | -5498.7% |
| Net Profit Margin | 8.1% | 8.1% | 11.0% | 8.5% | -5.4% | 25.8% | 8.6% | -7.7% | -14.0% | -262.9% | -5504.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 23.7% | 23.7% | 32.6% | 24.7% | -12.6% | 36.8% | 19.6% | -25.4% | -40.0% | -62.7% | -85.6% |
| ROA | 3.8% | 3.8% | 4.9% | 4.2% | -2.7% | 10.7% | 5.6% | -7.6% | -18.3% | -50.3% | -72.5% |
| ROIC | 14.0% | 14.0% | 15.5% | 18.4% | 5.0% | 4.8% | 38.8% | — | — | — | — |
| ROCE | 15.8% | 15.8% | 18.5% | 23.4% | 5.8% | 4.3% | 22.1% | -22.8% | -19.9% | -62.1% | -81.4% |
COLL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Collegium Pharmaceutical, Inc. carries a Debt/EBITDA ratio of 2.3x, which is manageable (30% below the sector average of 3.3x). Net debt stands at $689M ($941M total debt minus $251M cash). Interest coverage of just 2.1x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.12 | 3.12 | 3.75 | 3.45 | 3.64 | 1.28 | 1.43 | 0.25 | 0.13 | 0.01 | 0.03 |
| Debt / EBITDA | 2.28 | 2.28 | 2.53 | 2.13 | 4.12 | 2.99 | 2.26 | — | 0.13 | — | — |
| Net Debt / Equity | — | 2.29 | 3.45 | 2.23 | 2.75 | 0.36 | 0.50 | -1.70 | -1.48 | -1.13 | -1.11 |
| Net Debt / EBITDA | 1.67 | 1.67 | 2.33 | 1.38 | 3.11 | 0.84 | 0.79 | — | -1.50 | — | — |
| Debt / FCF | — | 2.10 | 3.88 | 1.59 | 4.37 | 0.71 | — | -6.95 | -0.93 | — | — |
| Interest Coverage | 2.13 | 2.13 | 2.33 | 1.91 | 0.54 | 0.84 | 1.95 | -24.00 | -0.94 | — | -1000.87 |
COLL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.57x means Collegium Pharmaceutical, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 1.17x to 1.57x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.57 | 1.57 | 0.95 | 1.17 | 0.97 | 1.13 | 1.16 | 1.27 | 1.27 | 4.24 | 6.92 |
| Quick Ratio | 1.48 | 1.48 | 0.88 | 1.10 | 0.86 | 1.07 | 1.10 | 1.22 | 1.23 | 4.18 | 6.86 |
| Cash Ratio | 0.92 | 0.92 | 0.32 | 0.68 | 0.40 | 0.67 | 0.73 | 0.84 | 0.78 | 3.77 | 6.68 |
| Asset Turnover | — | 0.47 | 0.38 | 0.50 | 0.40 | 0.40 | 0.48 | 0.97 | 0.96 | 0.21 | 0.01 |
| Inventory Turnover | 7.76 | 7.76 | 7.15 | 7.44 | 5.47 | 7.26 | 8.34 | 20.08 | 21.19 | 1.43 | 0.16 |
| Days Sales Outstanding | — | 98.82 | 132.10 | 115.61 | 144.07 | 139.54 | 98.10 | 89.75 | 101.46 | 127.78 | 454.17 |
COLL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Collegium Pharmaceutical, Inc. returns 2.1% to shareholders annually primarily through share buybacks. The earnings yield of 4.7% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | 6.5% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.7% | 3.7% | 6.5% | 4.2% | — | 10.0% | 3.8% | — | — | — | — |
| FCF Yield | 27.7% | 17.8% | 17.6% | 21.3% | 15.6% | 13.3% | — | 3.1% | 25.6% | — | — |
| Buyback Yield | 2.1% | 1.4% | 5.2% | 5.8% | 1.8% | 6.2% | 0.0% | 0.1% | 0.1% | 0.0% | 0.0% |
| Total Shareholder Yield | 2.1% | 1.4% | 5.2% | 5.8% | 1.8% | 6.2% | 0.0% | 0.1% | 0.1% | 0.0% | 6.5% |
| Shares Outstanding | — | $40M | $40M | $42M | $34M | $41M | $35M | $33M | $33M | $30M | $24M |
Peer Comparison
Compare COLL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 COLLYou | $1B | 21.1 | 4.5 | 3.6 | 59.3% | 24.0% | 23.7% | 14.0% | 2.3 |
 AVDL | $2B | -42.4 | — | — | 91.0% | -25.1% | -60.4% | -76.3% | — |
 HRMY | $2B | 12.1 | 5.0 | 5.4 | 77.2% | 24.0% | 20.8% | 59.5% | 0.1 |
 SUPN | $3B | -75.7 | 52.6 | 64.4 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 PCRX | $932M | 148.1 | 9.9 | 6.8 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 PRGO | $2B | -1.2 | 7.5 | 11.6 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 MCK | $91B | 28.9 | 18.5 | 17.4 | 3.5% | 1.2% | — | 540.6% | 1.5 |
 CAH | $45B | 29.7 | 16.5 | 24.4 | 3.7% | 1.0% | — | 3378.7% | 3.0 |
 CVS | $111B | 62.5 | 13.1 | 14.3 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 |
 NKTR | $2B | -8.7 | — | — | — | -253.7% | -217.9% | -75.2% | — |
 XTLB | $357581 | -0.3 | — | — | 0.7% | -481.6% | -26.8% | -54.1% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
See COLL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs COLL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare COLL vs AVDL
Side-by-side business, growth, and profitability comparison vs Avadel Pharmaceuticals plc.
Start ComparisonCOLL — Frequently Asked Questions
Quick answers to the most common questions about buying COLL stock.
What is Collegium Pharmaceutical, Inc.'s P/E ratio?
Collegium Pharmaceutical, Inc.'s current P/E ratio is 21.1x. The historical average is 20.5x. This places it at the 40th percentile of its historical range.
What is Collegium Pharmaceutical, Inc.'s EV/EBITDA?
Collegium Pharmaceutical, Inc.'s current EV/EBITDA is 4.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 6.6x.
What is Collegium Pharmaceutical, Inc.'s ROE?
Collegium Pharmaceutical, Inc.'s return on equity (ROE) is 23.7%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -37.8%.
Is COLL stock overvalued?
Based on historical data, Collegium Pharmaceutical, Inc. is trading at a P/E of 21.1x. This is at the 40th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Collegium Pharmaceutical, Inc.'s profit margins?
Collegium Pharmaceutical, Inc. has 59.3% gross margin and 24.0% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Collegium Pharmaceutical, Inc. have?
Collegium Pharmaceutical, Inc.'s Debt/EBITDA ratio is 2.3x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.